- Conditions
- Postoperative Nausea and Vomiting
- Interventions
- Automated recommendation at the start of the case, Automated notification at the start of surgery, Preoperative recommendations: by email, Automated notification at the end of surgery, Anesthesia Information Management System (AIMS), Perioperative Data Warehouse (PDW), General anesthesia, Elective surgery, Propofol, Sevoflurane, Isoflurane, Desflurane, Scopolamine, Droperidol, Haloperidol, Dexamethasone, Promethazine, Meclizine, Aprepitant, Metoclopramide, Fentanyl, Sufentanil, Alfentanil, Remifentanil, Morphine, Meperidine, Hydromorphone, Methadone, Oxycodone, Oxymorphone, Hydrocodone, Ketamine, Ondansetron, Granisetron, Dolasetron mesylate, Palonosetron, Tropisetron, Ramosetron
- Procedure · Device · Drug
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27,034 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 217–240
of 488
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pain, Abortion, Anxiety
- Interventions
- Diphenhydramine, Placebo
- Drug
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Primary Total Hip Arthroplasty, Primary Total Knee Arthroplasty
- Interventions
- Diphenhydramine (Benadryl), Melatonin, Sleep Hygiene Education
- Drug · Dietary Supplement · Behavioral
- Lead sponsor
- James A. Keeney
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Columbia, Missouri
- Conditions
- Schizophrenia, Schizo Affective Disorder, Treatment-resistant Schizophrenia
- Interventions
- Telmisartan Pill
- Drug
- Lead sponsor
- Xiaoduo Fan
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Worcester, Massachusetts
- Conditions
- Lung Cancer
- Interventions
- DOTAP:Chol-TUSC2, Erlotinib, Dexamethasone, Diphenhydramine
- Drug
- Lead sponsor
- Genprex, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Acute Lymphoblastic Leukemia, in Relapse, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory, Acute Lymphoblastic Leukemia With Failed Remission, B-cell Non Hodgkin Lymphoma, B Cell Leukemia
- Interventions
- CD19 specific Chimeric Antigen Receptor T Cell
- Biological
- Lead sponsor
- Nationwide Children's Hospital
- Other
- Eligibility
- Up to 30 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2035
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Migraine
- Interventions
- Hydromorphone, Prochlorperazine, Diphenhydramine
- Drug
- Lead sponsor
- Montefiore Medical Center
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Platinum Resistant Ovarian Cancer
- Interventions
- losartan, Paclitaxel
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2028
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Headache
- Interventions
- Ketorolac, Acetaminophen
- Drug
- Lead sponsor
- Corewell Health South
- Other
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Saint Joseph, Michigan
- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- obinutuzumab (RO5072759), rituximab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Denver, Colorado • Gainesville, Florida + 10 more
- Conditions
- Acute Myeloid Leukemia
- Interventions
- RO7283420, Tocilizumab, Dasatinib, Dexamethasone, Paracetamol/acetaminophen, Diphenhydramine
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 2
- States / cities
- Sacramento, California • Houston, Texas
- Conditions
- Hypersensitivity Reactions
- Interventions
- Dexamethasone
- Drug
- Lead sponsor
- Loma Linda University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- Loma Linda, California
- Conditions
- Pain
- Interventions
- Advil PM Liqui-Gels Minis, Advil PM Liqui-Gels
- Drug
- Lead sponsor
- HALEON
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 77 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Kidney, Polycystic
- Interventions
- Lisinopril, Telmisartan, Placebo
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 15 Years to 64 Years
- Enrollment
- 486 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 7
- States / cities
- Aurora, Colorado • Atlanta, Georgia • Kansas City, Kansas + 3 more
- Conditions
- Hypertension
- Interventions
- Amlodipine 5 mg, Placebo, Telmisartan 20 mg, Telmisartan 40 mg, Amlodipine 10 mg, Telmisartan 80 mg, Amlodipine 2.5 mg
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,461 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 101
- States / cities
- Fairhope, Alabama • Huntsville, Alabama • Chandler, Arizona + 81 more
- Conditions
- Pediatric Hypertension
- Interventions
- NICHE method, Usual care, Amlodipine, Lisinopril, Hydrochlorothiazide, Losartan
- Other · Drug
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 10 Years to 22 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Severe Obstructive Sleep Apnea (Apnea Hypopnea Index > 30 Events/Hour), Hypertension
- Interventions
- Losartan, Allopurinol, Placebo
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 4
- States / cities
- Green Bay, Wisconsin • La Crosse, Wisconsin • Madison, Wisconsin + 1 more
- Conditions
- Hypertension
- Interventions
- losartan potassium
- Drug
- Lead sponsor
- Roxane Laboratories
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004
- U.S. locations
- 1
- States / cities
- Springfield, Missouri
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia, Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Castration-Resistant Prostate Carcinoma, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid System Neoplasm, Locally Advanced Pancreatic Adenocarcinoma, Metastatic Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Primary Myelofibrosis, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Hematologic Malignancy, Recurrent Hodgkin Lymphoma, Recurrent Myelodysplastic Syndrome, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Myeloproliferative Neoplasm, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Recurrent Small Lymphocytic Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Chronic Myelomonocytic Leukemia, Refractory Hematologic Malignancy, Refractory Hodgkin Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Myelodysplastic Syndrome, Refractory Myelodysplastic/Myeloproliferative Neoplasm, Refractory Non-Hodgkin Lymphoma, Refractory Plasma Cell Myeloma, Refractory Primary Myelofibrosis, Refractory Small Lymphocytic Lymphoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
- Interventions
- Abemaciclib, Abiraterone, Afatinib, Bevacizumab, Bicalutamide, Biospecimen Collection, Bortezomib, Cabazitaxel, Cabozantinib, Capecitabine, Carboplatin, Celecoxib, Cobimetinib, Copanlisib, Dabrafenib, Dacomitinib, Darolutamide, Dasatinib, Doxorubicin, Durvalumab, Enasidenib, Entrectinib, Enzalutamide, Erlotinib, Everolimus, Fluorouracil, Idelalisib, Imatinib, Ipilimumab, Lenvatinib, Leucovorin, Lorlatinib, Losartan, Nab-paclitaxel, Neratinib, Nivolumab, Olaparib, Oxaliplatin, Palbociclib, Panobinostat, Pembrolizumab, Pertuzumab, Ponatinib, Quality-of-Life Assessment, Regorafenib, Ruxolitinib, Sirolimus, Sorafenib, Sunitinib, Trametinib, Trastuzumab Emtansine, Tretinoin, Vemurafenib, Venetoclax, Vismodegib, Vorinostat
- Drug · Biological · Procedure + 1 more
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Therapeutic Equivalence
- Interventions
- BAY98-7111, Naproxen Sodium (Aleve, BAYH6689), Diphenhydramine HCl
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Hackensack, New Jersey
- Conditions
- Emphysema
- Interventions
- Losartan, Placebo
- Drug
- Lead sponsor
- JHSPH Center for Clinical Trials
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • Tucson, Arizona • San Diego, California + 18 more
- Conditions
- T-cell Type Acute Leukemia-Precursor, T-lymphoblastic Lymphoma/Leukaemia
- Interventions
- Isatuximab SAR650984, dexamethasone, acetaminophen, ranitidine, diphenhydramine
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • Hackensack, New Jersey • Houston, Texas
- Conditions
- Pain
- Interventions
- Naproxen sodium 440 mg/DPH 50 mg (BAY98-7111), Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 326 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 19
- States / cities
- Chandler, Arizona • Mesa, Arizona • Peoria, Arizona + 16 more
- Conditions
- Microalbuminuria
- Interventions
- benazepril
- Drug
- Lead sponsor
- Charles Drew University of Medicine and Science
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 1
- States / cities
- Los Angeles, California